Product Monographs for
and for specific questions or detailed information
PrENERZAIR® Breezhaler® (indacaterol/ glycopyrronium/ mometasone furoate) is Indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.
Recommended dose for patients ≥18 years of age:
- Inhalation of the content of one capsule of ENERZAIR® BREEZHALER® 150/50/160 micrograms once daily in patients not adequately controlled with a combination of a LABA and a medium or high dose of an ICS.
PrENERZAIR® Breezhaler® (indacaterol/ glycopyrronium/ mometasone furoate) is Indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.
Recommended dose for patients ≥18 years of age:
- Inhalation of the content of one capsule of ENERZAIR® BREEZHALER® 150/50/160 micrograms once daily in patients not adequately controlled with a combination of a LABA and a medium or high dose of an ICS.
Accordion Content
Click here to download and consult the product monograph for important information on:
- Relevant warnings and precautions regarding serious asthma-related events, treatment of acute asthma symptoms, acutely deteriorating asthma, stopping ENERZAIR® BREEZHALER®, excessive use and use with other LABA products, worsening of narrow-angle glaucoma, worsening of urinary retention, cardiovascular effects, patients with known or suspected prolongation of the QT interval, localized infections of the mouth and throat, systemic corticosteroid effects, hypercorticism and adrenal suppression, adrenal insufficiency after transfer from systemic to inhaled corticosteroids, reduction in bone mineral density and monitoring requirements, hyperglycemia and monitoring requirements, hypokalemia and monitoring requirements, co-existing conditions, eosinophilic conditions, hypersensitivity, infections, monitoring and laboratory tests for serum potassium levels blood glucose in diabetic patients, bone and ocular effects in patients at risk, and corticosteroid effects for patients with severe hepatic impairment, risks associated with established glaucoma, paradoxical bronchospasm, use in pregnant and breast-feeding women, and hepatic and renal impairment.
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.
The product monograph is also available by calling Valeo Pharma at 1-855-694-0151.
Watch the product administration video for patients here.
Reference: ENERZAIR® BREEZHALER® Product Monograph. Novartis Pharmaceuticals Canada Inc. November 25, 2020. November 25, 2021. April 21, 2023.
PrATECTURA® Breezhaler® (indacaterol/ mometasone furoate) is a combination of a long-acting beta2-adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) indicated as a once daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease.
Recommended dose for patients ≥12 years of age:
- Inhalation of the content of one capsule of ATECTURA® BREEZHALER® 150/80 μg once daily in patients who require a combination of a LABA and a low dose of ICS.
- Inhalation of the content of one capsule of ATECTURA® BREEZHALER® 150/160 μg or 150/320 μg once daily in patients who require a combination of a LABA and a medium or high dose of ICS.
PrATECTURA® Breezhaler® (indacaterol/ mometasone furoate) is a combination of a long-acting beta2-adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) indicated as a once daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease.
Recommended dose for patients ≥12 years of age:
- Inhalation of the content of one capsule of ATECTURA® BREEZHALER® 150/80 μg once daily in patients who require a combination of a LABA and a low dose of ICS.
- Inhalation of the content of one capsule of ATECTURA® BREEZHALER® 150/160 μg or 150/320 μg once daily in patients who require a combination of a LABA and a medium or high dose of ICS.
Accordion Content
Click here to download and consult the product monograph for important information on:
- Relevant warnings and precautions regarding serious asthma-related events, treatment of acute asthma symptoms, acutely deteriorating asthma, stopping ATECTURA® BREEZHALER®, excessive use and use with other LABA products, cardiovascular effects, patients with known or suspected prolongation of the QT interval, localized infections of the mouth and throat, systemic corticosteroid effects, effect on growth, hypercorticism and adrenal suppression, adrenal insufficiency after transfer from systemic to inhaled corticosteroids, reduction in bone mineral density and monitoring requirements, hyperglycemia and monitoring requirements, hypokalemia and monitoring requirements, co-existing conditions,eosinophilic conditions, hypersensitivity, infections, monitoring and laboratory tests for serumpotassium levels blood glucose in diabetic patients, bone and ocular effects in patients at risk, and corticosteroid effectsfor patients with severe hepatic impairment, risks associated with established glaucoma, paradoxical bronchospasm, use in pregnant and breast-feeding women, and hepatic and renal impairment.
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.
The product monograph is also available by calling Valeo Pharma at 1-855-694-0151.
Watch the product administration video for patients here.
Reference: ATECTURA® BREEZHALER® Product Monograph. Novartis Pharmaceuticals Canada Inc. November 12, 2021. April 21, 2023.